Christian Angermayer - Jun 17, 2021 Form 3/A - Amendment Insider Report for ATAI Life Sciences N.V. (ATAI)

Role
Director, 10%+ Owner
Signature
/s/ Ryan Barrett, Attorney-in-fact
Stock symbol
ATAI
Transactions as of
Jun 17, 2021
Transactions value $
$0
Form type
3/A - Amendment
Date filed
8/25/2021, 04:00 PM
Date Of Original Report
Jun 17, 2021
Next filing
Jun 24, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATAI Common Shares 27.8M Jun 17, 2021 By Apeiron Investment Group Ltd. F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATAI Convertible Notes Jun 17, 2021 Common Shares 2.37M By Apeiron Investment Group Ltd. F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person's original Form 3 and subsequently filed Form 4 inadvertently understated this amount by 8,320,000 shares.
F2 Apeiron Investment Group Ltd. is the co-managing member of Presight Capital Management I, LLC, which is the general partner of Presight II, L.P. Therefore, Apeiron Investment Group Ltd. may be deemed to share beneficial ownership of the Common Shares held by Presight II, L.P. Apeiron Investment Group Ltd. is owned and controlled by Christian Angermayer. Mr. Angermayer may be deemed to have beneficial ownership over the shares held by Apeiron Investment Group Ltd. and Presight II, L.P.
F3 The Convertible Notes are currently exercisable and will mature on September 30, 2025.
F4 The reporting person's original Form 3 inadvertently overstated this amount by 5,952,800 shares.
F5 The conversion price for the Convertible Notes is Euro 17.00 per share.